Shortly after the original publication of Gentles1 on the effectiveness of griseofulvin in Trichophyton infections of laboratory animals, numerous investigators have reported on striking clinical results obtained with the oral administration of griseofulvin in treatment of superficial dermatomycoses in man. Williams et al.,2 Riehl,3 Blank and Roth,4 and Pardo-Castello5 were among the first attempting such clinical studies.
A main purpose of this paper is to evalu ate the recurrences noted in patients either after completion of a course of oral therapy with griseofulvin or in evidence during the course of treatment. The management of these cases will be discussed.
Several patients, moreover, were found to have persistently positive mycological laboratory findings despite apparent clinical cure. This situation we have designated as the "healthy carrier state."
We wish to call attention to the fact that our studies commenced in the winter months and extended into
GOLDFARB NJ, SULZBERGER MB. Experiences in One Hundred Thirty-Seven Patients Treated with Oral GriseofulvinSpecial Reference to Clinical Recurrences, the Healthy Carrier State, and Their Management. AMA Arch Derm. 1960;81(5):859–862. doi:10.1001/archderm.1960.03730050215038